Start with identity
NAD+ is nicotinamide adenine dinucleotide, a cofactor tracked alongside peptide-market claims. It is not itself a peptide sequence.
Checklist
Separate biology from claims
A basic biochemical role does not mean an NAD+ product improves energy, cognition, withdrawal symptoms, longevity, detoxification, performance, or wellness outcomes.
Read FDA sterile-risk sources first
FDA has flagged ingredient-suitability, supplier-quality, and adverse-event concerns around sterile compounded NAD+ products. Those FDA sources support caution about sterile compounded products; they are not route or administration directions.
Do not treat bulk lists as approval
FDA 503A and 503B bulk-substance lists deal with whether ingredients may be used in compounding. They do not make an NAD+ injectable finished product FDA-approved or clinically useful.
Trial records answer narrow questions
ClinicalTrials.gov records can show disease-specific research questions. They do not automatically carry over to wellness-infusion, clinic-market, or protocol claims.
Sources
- 1.
Other. PubChem Compound Summary for beta-Nicotinamide adenine dinucleotide 2026.
Accessed 2026-06-09.
NIH PubChem identity source for beta-nicotinamide adenine dinucleotide; used to separate NAD+ chemical identity from peptide sequence records and intervention claims.
- 2.
FDA. FDA reminds compounders to use ingredients suitable for sterile compounding 2024.
Accessed 2026-06-09.
FDA alert describing ingredient-suitability concerns for sterile compounded products, including NAD+ examples and reported adverse events consistent with endotoxin-related reactions.
- 3.
FDA. FDA to Compounders: Know Your Bulks and Excipients Suppliers 2026.
Accessed 2026-06-09.
FDA supplier-quality guidance for compounders; used for product-quality context, not as evidence of NAD+ efficacy or route instructions.
- 4.
FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A 2026.
Accessed 2026-06-09.
FDA 503A nominated bulk-substance category document listing nicotinamide adenine dinucleotide context; this is compounding policy context, not finished-product approval.
- 5.
FDA. 503B Bulk Drug Substances List 2023.
Accessed 2026-06-09.
FDA 503B bulk-substance list context for outsourcing facilities; used to distinguish compounding policy status from product approval or clinical evidence.
- 6.
FDA. GenoGenix LLC warning letter 2026.
Accessed 2026-06-09.
FDA warning letter discussing NAD+ compounded drug products and 503B exemption conditions; used for regulatory context.
- 7.
ClinicalTrials.gov. A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia 2026.
NCT06776510 Accessed 2026-06-09.
Registry source for a disease-specific NAD research question; used as trial-tracking context, not support for wellness or infusion claims.
- 8.
ClinicalTrials.gov. Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome 2026.
NCT04604704 Accessed 2026-06-09.
Registry source for a low-dose naltrexone and NAD+ post-COVID study; used as trial-tracking context without publishing protocol or dose instructions.